LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by F M Investments LLC

F M Investments LLC raised its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 36.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 123,545 shares of the medical instruments supplier's stock after buying an additional 33,087 shares during the quarter. F M Investments LLC owned approximately 0.55% of LeMaitre Vascular worth $11,476,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LMAT. Vanguard Group Inc. grew its holdings in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier's stock valued at $87,914,000 after buying an additional 38,303 shares in the last quarter. Norden Group LLC purchased a new position in shares of LeMaitre Vascular during the 1st quarter worth $401,000. BNP Paribas Financial Markets grew its holdings in shares of LeMaitre Vascular by 135.6% during the 1st quarter. BNP Paribas Financial Markets now owns 22,917 shares of the medical instruments supplier's stock worth $1,521,000 after purchasing an additional 13,189 shares during the period. Whitegate Investment Counselors Inc. purchased a new position in shares of LeMaitre Vascular during the 1st quarter worth $216,000. Finally, Texas Permanent School Fund Corp grew its holdings in shares of LeMaitre Vascular by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier's stock worth $1,151,000 after purchasing an additional 225 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

LMAT stock traded up $6.49 during mid-day trading on Friday, reaching $94.88. The company had a trading volume of 343,645 shares, compared to its average volume of 105,134. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of 51.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.89. The firm has a fifty day simple moving average of $89.59 and a 200 day simple moving average of $83.11. LeMaitre Vascular, Inc. has a fifty-two week low of $45.96 and a fifty-two week high of $101.67.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.39% and a net margin of 19.40%. LeMaitre Vascular's revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.33 EPS. As a group, analysts predict that LeMaitre Vascular, Inc. will post 1.86 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is currently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of the firm's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now owns 14,114 shares of the company's stock, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on LMAT. Barrington Research increased their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a report on Friday. JMP Securities increased their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 20th. StockNews.com cut LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Tuesday, August 27th. Cantor Fitzgerald began coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 target price for the company. Finally, Oppenheimer restated an "outperform" rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a report on Friday. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.